Iteos Home

Press Releases

Home / Investors / iTeos Therapeutics SA today announced the appointment of Yves Mertens as Chief Financial Officer

Press Release Details

iTeos Therapeutics SA today announced the appointment of Yves Mertens as Chief Financial Officer

April 27, 2016
PDF Version

Gosselies, Belgium – April 27, 2016 – iTeos Therapeutics SA, a biotechnology company delivering therapeutics targeting the immune tumor micro-environment to develop cancer immunotherapies, today announced that Yves Mertens will be responsible for structuring the administration and finance aspects of iTeos’ operations to support its further expansion.

 

"We are delighted that Yves has decided to join iTeos as a key member of our executive team, as iTeos enters into a new phase in its rapid development whereby it expands its own proprietary drug targets and drug discovery activities. Yves is a highly experienced senior financial executive with over 25 years of international business experience and corporate development" stated Michel Detheux, CEO. "Yves brings invaluable experience to the organization that will be essential for building a successful company as we progress into our next stages of corporate development."

 

Before joining iTeos, Yves Mertens’ most recent position was as the CEO at Aliaxis for six years after holding CFO positions for 12 years. “I am excited to take on the challenge of the CFO position at iTeos in this formative and rapidly growing stage for the company”, said Yves Mertens. “iTeos has the science and technologies to become a key player in cancer immunotherapy, and I look forward to helping to make that happen.”

 

About iTeos Therapeutics SA

Based in Gosselies, Belgium, iTeos, a spin-off of Ludwig Cancer Research (LICR) and de Duve Institute (UCL), has built a discovery platform to identify therapeutics targeting the immune tumor micro-environment to optimize cancer immunotherapy and is now positioned to help deliver the next generation of cancer immunotherapies. iTeos combines expertise in tumor immunology with drug discovery of small molecules and biologics. The company entered into a strategic collaboration with Pfizer in December 2014 and with Adimab in January 2016. iTeos is developing partnerships with top-tier academic and industrial partners to develop new programs. iTeos is supported by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development).

For investors

scientist picking up a petri dish

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.

Driven by a culture of scientific innovation, collaboration and excellence, together we discover and deliver breakthrough immunotherapies to improve and extend the lives of people with cancer.